CRISPR Therapeutics AG Price to Free Cash Flow Ratio 2015-2021 | CRSP

Historical price to free cash flow ratio values for CRISPR Therapeutics AG (CRSP) since 2015. For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
CRISPR Therapeutics AG Price to Free Cash Flow Ratio Historical Data
Date Stock Price TTM FCF per Share Price to FCF Ratio
2022-01-19 64.19 11.14
2021-09-30 111.93 $5.76 19.42
2021-06-30 161.89 $5.88 27.53
2021-03-31 121.85 $-4.42 0.00
2020-12-31 153.11 $-3.89 0.00
2020-09-30 83.64 $-2.36 0.00
2020-06-30 73.49 $1.01 72.59
2020-03-31 42.41 $0.83 50.96
2019-12-31 60.91 $0.88 69.36
2019-09-30 40.99 $0.23 177.45
2019-06-30 47.10 $-2.59 0.00
2019-03-31 35.72 $-2.42 0.00
2018-12-31 28.57 $-2.06 0.00
2018-09-30 44.35 $-1.85 0.00
2018-06-30 58.76 $-1.89 0.00
2018-03-31 45.71 $-1.78 0.00
2017-12-31 23.48 $-1.94 0.00
2017-09-30 17.87 $-6.33 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $4.978B $0.001B
CRISPR Therapeutics AG is a gene-editing company. It focused on the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 gene-editing platform. CRISPR Therapeutics AG is headquartered in Basel, Switzerland.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.033B 9.10
Bio-Rad Laboratories (BIO.B) United States $17.971B 36.47
QIAGEN (QGEN) Netherlands $11.044B 18.70
Biohaven Pharmaceutical Holding (BHVN) United States $7.729B 0.00
Emergent Biosolutions (EBS) United States $2.541B 9.14
Arcus Biosciences (RCUS) United States $2.414B 0.00
Myovant Sciences (MYOV) United Kingdom $1.374B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.167B 0.00
Zymeworks (ZYME) Canada $0.623B 0.00
Ambrx Biopharma (AMAM) United States $0.231B 0.00
SQZ Biotechnologies (SQZ) United States $0.214B 0.00
Enzo Biochem (ENZ) United States $0.161B 20.75